Overactive Bladder (OAB) Clinical Trial
Official title:
A Randomized, Double Blind, Placebo Controlled Detrol LA "Add-On" To Alpha-Blocker Study In Men With Persistent Overactive Bladder Symptoms Of Urinary Frequency And Urgency With/Without Urgency Incontinence After Previous Monotherapy With Alpha Blocker.
An interventional active/placebo double blinded parallel randomized controlled study in which at 12 weeks of treatment, the primary endpoint of patient perception of bladder condition is measured along with associated safety and other secondary endpoints like bladder diary endpoints, quality of life and patient treatment satisfaction. Patients included in the study must have symptoms of OAB (frequency of at least 8 per day and Urgency of at least 1 episode per day confirmed by bladder diary). Patients are not eligible to enroll in the study if they have/had significant hepatic or renal disease, history of radiation treatment.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT00507169 -
SVT-40776 in Patients Suffering From Overactive Bladder Syndrome
|
Phase 2 | |
| Completed |
NCT02216214 -
Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Older Adult Subjects With Overactive Bladder (OAB)
|
Phase 4 | |
| Completed |
NCT02294396 -
Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
|
Phase 4 | |
| Completed |
NCT01936870 -
Drug Use Investigation for Toviaz
|
||
| Completed |
NCT03846895 -
Vaginal CO2 Laser in Postmenopausal Women With Overactive Bladder Syndrome (OAB)
|
N/A | |
| Completed |
NCT03903094 -
A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
|
||
| Terminated |
NCT04451382 -
PTNS vs Botox of Refractory OAB
|
||
| Terminated |
NCT04641975 -
A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB)
|
Phase 3 | |
| Completed |
NCT00366002 -
Patient's Perception of Treatment Outcome With Darifenacin by Patients With Overactive Bladder
|
Phase 4 | |
| Completed |
NCT02138747 -
A Study to Evaluate Tolerability and Participants Preference Between Mirabegron and Tolterodine Extended Release (ER) in Participants With Overactive Bladder (OAB)
|
Phase 4 | |
| Completed |
NCT03602508 -
Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
|
||
| Completed |
NCT03572231 -
A Registry Study of Patients Initiating a Course of Drug Therapy for Overactive Bladder in Taiwan, Korea and China
|
||
| Completed |
NCT05211193 -
Open Label Study to Evaluate the Efficacy of the Home Based Electrical Transcutaneous URIS I in the Treatment of Overactive Bladder (OAB).
|
||
| Completed |
NCT04562090 -
A Study With Mirabegron 50 mg and 25 mg in Chinese Participants With Overactive Bladder
|
Phase 4 | |
| Completed |
NCT01639794 -
Vesitirim™ in Men Postmarketing Observational Study
|
N/A | |
| Withdrawn |
NCT01317810 -
A Study Measuring and Tracking Changes in Overactive Bladder (OAB) Medication
|
N/A | |
| Completed |
NCT00742833 -
A Phase II Study of KUC-7483 in Patients With Overactive Bladder
|
Phase 2 |